The clinical evidence that p140Cap correlates with a favorable outcome in ERBB2 breast cancer patients suggest that p140Cap is able to curb the intrinsic biological aggressiveness of ERBB2 tumor (Grasso et al., 2017). The gene discussed is ERBB2; the disease is breast carcinoma.